26 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of novel benzimidazole series of potent and selective ORL1 antagonists.
Banyu Tsukuba Research Institute
Cyclohexylmethylpiperidinyltriphenylpropioamide: a selective muscarinic M(3) antagonist discriminating against the other receptor subtypes.
Banyu Tsukuba Research Institute
Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Banyu Tsukuba Research Institute
The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators.
Banyu Tsukuba Research Institute
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Banyu Tsukuba Research Institute
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
Banyu Tsukuba Research Institute
Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.
Banyu Tsukuba Research Institute
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.
Banyu Tsukuba Research Institute
Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.
Banyu Tsukuba Research Institute
Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Banyu Tsukuba Research Institute
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Banyu Tsukuba Research Institute
Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.
Banyu Tsukuba Research Institute
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.
Banyu Tsukuba Research Institute
Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists.
Banyu Tsukuba Research Institute
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.
Banyu Tsukuba Research Institute
N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist.
Banyu Tsukuba Research Institute
Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.
Banyu Tsukuba Research Institute
A new class of type I protein geranylgeranyltransferase (GGTase I) inhibitor.
Banyu Tsukuba Research Institute
Synthesis and biological activities of NB-506 analogues modified at the glucose group.
Banyu Tsukuba Research Institute
Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
Banyu Tsukuba Research Institute
Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.
Merck Research Laboratories